1-6 of 6
Samuel Suzuki
Close
Sort by
Journal Articles

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Clinical Trials & Observations
Paul M. Barr, Jennifer R. Brown, Peter Hillmen, Susan O'Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Stephen P. Mulligan, Ulrich Jaeger, Richard R. Furman, Florence Cymbalista, Marco Montillo, Claire Dearden, Tadeusz Robak, Carol Moreno, John M. Pagel, Jan A. Burger, Samuel Suzuki, Juthamas Sukbuntherng, George Cole, Danelle F. James, John C. Byrd
Journal: Blood
Blood (2017) 129 (19): 2612–2615.
https://doi.org/10.1182/blood-2016-12-737346
Published: 2017
Includes: Supplemental data
Journal Articles

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert W Chen, MD, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, M. Lia Palomba, MD
Journal: Blood
Blood (2016) 128 (22): 1804.
https://doi.org/10.1182/blood.V128.22.1804.1804
Published: 2016
Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD
Journal: Blood
Blood (2016) 128 (22): 4383.
https://doi.org/10.1182/blood.V128.22.4383.4383
Published: 2016
Journal Articles

Changes in Clinical Stage Identify Different Response Categories Among Patients in Iwcll PR: Analysis of CLL Patients on the Resonate Study

Carol Moreno, MD, Julio Delgado, MD, John C. Byrd, MD, William L. Zvagelsky, Samuel Suzuki, MS, MBA, Emily Hsu, PhD, Danelle F. James, MD MAS, Emili Montserrat, MD
Journal: Blood
Blood (2016) 128 (22): 4384.
https://doi.org/10.1182/blood.V128.22.4384.4384
Published: 2016
Journal Articles

Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert Chen, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD, Jutta K. Neuenburg, MD, M. Lia Palomba, MD
Journal: Blood
Blood (2015) 126 (23): 470.
https://doi.org/10.1182/blood.V126.23.470.470
Published: 2015
Journal Articles

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jacqueline C. Barrientos, MD, Susan O'Brien, Jennifer R. Brown, MD PhD, Neil E. Kay, MD, Nishitha M. Reddy, MBBS, Steven Coutre, MD, Constantine Tam, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Ulrich Jaeger, MD, Steve Devereux, MD, Christopher Pocock, MD PhD, Tadeusz Robak, MD, Stephen J. Schuster, MD, Anna Schuh, MDPhD, Devinder Gill, MD, Adrian Bloor, PhD FRCPath, Claire Dearden, MD, Carol Moreno, MD, Gavin Cull, MBBS, DM, FRACP, FRCPA, Michael Hamblin, Jeffrey A. Jones, MD, Tanja Kierschniak, Karl Eckert, BA, Samuel Suzuki, MS, MBA, Emily Hsu, PhD, Danelle F. James, MD MAS, John C. Byrd, MD, Peter Hillmen, MB, ChB, PhD
Journal: Blood
Blood (2014) 124 (21): 4696.
https://doi.org/10.1182/blood.V124.21.4696.4696
Published: 2014